Our achievements. Our accomplishments. Our impact.



  • Stem Cell Plasticity

    Adult stem cells offer great potential as tools or targets of new treatments, and the Stem Cell Network launched a multidisciplinary project early in its mandate in order to discover more about the nature of these mysterious cells.

    READ STORY

  • Establishing a Community

    By prioritizing multidisciplinary research partnerships among stem cell researchers across Canada, the Stem Cell Network integrated the country’s previously fractured landscape into a comprehensive and globally respected research community.

    READ STORY

  • Commercialization

    The Stem Cell Network’s catalysis of commercialization of stem cell research has led to 399 patent applications, 60 issued patents, 43 licenses granted, the growth or launch of 11 start-up biotechnology companies and the establishment of a new Centre for the Commercialization of Regenerative Medicine (CCRM) to develop a strong industry presence in several emerging technology areas likely to be crucial to the future delivery of stem cell-based therapies.

    READ STORY

  • Catalyzing New Organizations

    The Stem Cell Network was critical for strategically identifying structural gaps in the Canadian stem cell research landscape and bringing together diverse stakeholder groups to seize those opportunities through the incubation and launch of new organizations.

    READ STORY

  • Drug Discovery and Repurposing

    The Stem Cell Network was among the first organizations to recognize the potential of using stem cells for drug repositioning and discovery in order to reduce time and costs of bringing new therapies to patients, and in the process has established Canada as a world leader in the field.

    READ STORY

  • Cancer Stem Cells

    A seminal Canadian discovery demonstrated that cancer stem cells are a significant reason for high relapse rates after cancer treatments. In recognition of this, the Stem Cell Network has invested heavily finding ways to target and attack them.

    READ STORY